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ANTI-GVHD EFFECT OF ANTITHYMOCYTE GLOBULIN IS MEDIATED BY
ANTIBODIES BINDING TO T CELLS AND REGULATORY NK CELLS, AND
LESS SO OR NOT AT ALL BY ANTIBODIES BINDING TO OTHER MONONU-
CLEAR CELL SUBSETS
Hoegh-Petersen, M., Amin, M., Liu, Y., Ugarte-Torres, A.,
Williamson, T.S., Podgorny, P.J., Russell, J.A., Storek, J. University of
Calgary, Calgary, AB, Canada
Introduction: Polyclonal rabbit-anti-human T cell globulin (ATG)
may decrease the likelihood of graft-vs-host disease (GVHD) with-
out increasing the likelihood of relapse. ATG is polyclonal and the
anti-GVHD effect may be mediated through killing/inhibition of
one or several lymphocyte subsets (eg, T cells) or their subsets (eg,
na€ıve T cells). To understand the mechanism of action of ATG on
GVHD, we determined levels of which ATG fraction (capable of
binding to which cell subset) are associated with subsequent develop-
ment of GVHD.
Patients &Methods:We studied 121 patients whose myeloablative
conditioning included 4.5 mg/kg ATG (Thymoglobulin). Using
flow cytometry, levels of the following ATG fractions in serum
from day 7 were determined: capable of binding to naive or memory
B cells; naive, central memory (CM) or effector memory (EM) CD4
andCD8Tcells,EMCD8Tcells not expressingCD45RA (EMRA-);
cytolytic, regulatory or CD16+CD56- NK cells; monocytes and den-
dritic cells (DCs). ATG levels in patients with vs without aGVHD
or cGVHD were compared using Mann-Whitney test. For each
fractionwhere levels were significantly different (p\0.05), we deter-
mined if patients with high fraction level had a significantly lower
likelihood of aGVHD or cGVHD using log-binomial regression
models.
Results: In univariate analyses, significantly lower levels of ATG
fractions on the following subsets were found in patients developing
aGVHD: binding to naive CD4 and CD8 T cells, EM CD4 T cells,
and regulatoryNK cells, or cGvHD: binding to naive CD4 and CD8
T cells, CM and EM CD4 T cells, and regulatory NK cells. In mul-
tivariate analyses, high levels of the following ATG fractions were as-
sociated with a low likelihood of aGVHD: binding to naive CD4 T
cells (RR 5 .33, p 5 .001), EM CD4 T cells (RR 5 .30, p\ .001),
naive CD8 T cells (RR 5 .33, p 5 .002) and regulatory NK cells
(RR5 .36, p5 .001) or low likelihood of cGVHD: binding to naive
CD4 T cells (RR5 .59, p5 .028), CMCD4 T cells (RR5 .49, p5
.009), EMCD4T cells (RR5 .51, p5 .006), naive CD8 T cells (RR
5 .46, p 5 .005) and regulatory NK cells (RR 5 .55, p 5 .036).
Conclusion: For both aGVHD and cGVHD, the anti-GVHD ef-
fect with relapse-neutral effect of ATGappears to bemediated by an-
tibodies to antigens expressed on naive T cells (both CD4 and CD8),
EM CD4 T cells and regulatory NK cells. This is the first step to-
wards identifying the antibody(ies) within ATG important for the
anti-GVHD effect without impacting relapse.481
DISSECTING THE MECHANISMS OF GVHD CONTROL: USING THE PRI-
MATE GVHD MODEL TO DETERMINE THE ROLE THAT SIROLIMUS PLAYS
IN GVHD PREVENTION
Srinivasan, S.2, Blazar, B.R.3, Kean, L.S.1 1Emory University; 2Emory
University; 3University of Minnesota
The Rhesus Macaque GvHD Model is uniquely able to support
a mechanistic dissection of the contribution that individual immuno-
modulating agentsmake toGvHDprevention, in a clinically relevant
primate system. In this study, we determined the primarymechanism
by which sirolimus prevents GvHD in primates. Rhesus macaques
underwent MHC-mismatched HSCT while receiving sirolimus
monotherapy (sirolimus trough5-15 ng/mL). Recipients exhibited
modestly prolonged survival compared to untreated controls
(MST . 19 days versus 6.5 days in controls).
Sirolimus markedly inhibited T cell proliferation in transplanted
animals. Thus, while CD4+ and CD8+ T cells expanded by as
much as 300-fold and 2000-fold, respectively, in the absence of im-
munoprophylaxis, in sirolimus-treated animals, the accumulation of
these cells was significantly blunted, with their expansion being only
4- and 3.6-fold, respectively compared to the post-TBI nadir.
Consistent with this marked impact on T cell proliferation, siroli-
mus-treated recipients also better controlled the upregulation ofthe proliferation marker Ki-67 on CD4+ or CD8+ T cell subpopu-
lations. Thus, while untreated recipients upregulated Ki-67 expres-
sion by as much as 10-fold after engraftment, (with . 80-98% of
both CD4+ and CD8+ T cells expressing high levels of Ki-67
post-transplant versus 5-10% pre-transplant) sirolimus-treated
recipients displayed blunted Ki-67 expression (with an average of
only 29% of both CD4+ and CD8+ T cells expressing high levels
of Ki-67 post-transplant).
While the impact of sirolimus on T cell proliferation was pro-
found, its impact on the expression of CD127 (the IL-7Ra), a marker
of T cell activation, was small. Thus, similar to the untreated control
animals, who demonstrated a total loss of CD127 in the context of
severe clinical GvHD, up to 60% of CD8+ T cells in sirolimus-
treated recipients down-regulated CD127, consistent with break-
through activation and functional maturation of these cells despite
mTOR inhibition.
These results indicate that the predominant effect of sirolimus
during primate GvHD prophylaxis is its striking ability to inhibit
T cell proliferation. These results imply that therapies that are added
to sirolimus to achieve multimodal GvHD prevention should be
directed at inhibiting T cell activation and function rather than pro-
liferation, in order to target non-redundant pathways of alloimmune
activation during GvHD control.482
REQUIREMENT AND PLASTICITY OF CD4+FOXP3+ T REGULATORY
CELLS (TREGS) IN GVHD PREVENTION WITH HIGH-DOSE POSTTRANS-
PLANT CYCLOPHOSPHAMIDE (HICY) IN MICE AND HUMANS
Ganguly, S., Kos, F., Thoburn, C., Jones, R.J., Hess, A., Luznik, L. Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins University,
Baltimore, MD
Administration of HiCy in murine models of alloBMT and as
a short course single agent GVHD prophylaxis in a HLA-matched
setting offers a promising model for evaluating the efficacy and fail-
ure of postgrafting immunosuppression. To investigate whether
Tregs and especially their plasticity have a role in modulation of
GVHD by HiCy, parallel studies were performed in a MHC-
matched mouse model of alloBMT and on patient peripheral
lymphocytes after alloBMT. For the former, we used C57Bl/6-
Foxp3-DTR-luciferase+ mice (H-2b, CD45.2+) as donors, in which
Tregs were depleted by diptheria toxin (DT) administration and
the in vivo fate of adoptively transferred cells in irradiated Balb/b re-
cipients (H-2b, CD45.2+) was tracked by bioluminescent imaging
(BLI). On day 4 post-BMT, DT-treated animals had greater biolu-
minescence (photons/second) compared to controls (p \ 0.001).
HiCy treatment on day 3 post-BMT dampened proliferation of
alloreactive T cells on days 4, 7, 14 and 21 (p \ 0.05; HiCy vs
DT-treated chimeras and controls). Treg depletion in HiCy recipi-
ents promoted donor T-cell expansion, suggesting that Tregs were
vital to the protective action of HiCy. GVHD was more severe in
Treg-depleted chimeras (P\0.05, compared to controls) and absent
in HiCy-treated animals (P\ 0.01, HiCy vs PBS- and DT-treated
chimeras). HiCy-mediated protection was offset by Treg ablation,
resulting in increased morbidity and mortality. The development
of GVHD in untreated and Treg-depleted HiCy-treated chimeras
was associated with emergence of CD4+Foxp3+IFN-g-producing
cells. To overcome heterogeneity in human Foxp3 expression, we ex-
amined three phenotypically and functionally distinct Treg subsets
based on expression of CD25, Foxp3 and CD45RA. We found
that patients with acute GVHD had a substantial increase in the
CD25++CD45RA-Foxp3lo subset of cytokine-producing cells with
low suppressive ability (p \ 0.05, compared to healthy donors).
Interestingly, proportions of both CD25+++CD45RA-Foxp3hi
activated Tregs and the naive CD25++CD45RA+Foxp3lo subset
were retained in GVHD-free patients.We conclude that persistence
of CD4+Foxp3+ Tregs is required for HiCy-mediated control of
GVHD. In humans, CD45RA+ Tregs can survive exposure to
HiCy and presumably maintain the Foxp3+ Treg pool. The emer-
gence of the Foxp3lo IFN-g-producing population in both mice
and humans underscores the importance of examining functional
plasticity of CD4+Foxp3+ T cell subsets in relation to the develop-
ment of GVHD.
